🏭 This partnership will enhance Lonza’s capabilities in particle technology and drug product development.
🌐 Lonza gains access to CMAC’s network, advancing drug manufacturing efficiency and quality.
🤝 Experts will collaborate to apply best practices in continuous processing and CMC strategies, benefiting customers.
Introduction:
The article discusses Lonza’s recent collaboration with the Center for Continuous Manufacturing and Advanced Crystallization (CMAC) based at the University of Strathclyde in Glasgow, Scotland. This partnership aims to enhance particle technologies and drug product development through innovative manufacturing processes.
- Lonza has joined CMAC, a research hub focused on transforming pharmaceutical manufacturing through continuous manufacturing technologies.
- CMAC aims to optimize efficiency and improve product quality within the pharmaceutical sector by facilitating applied research and translation to industry.
- Lonza will leverage CMAC’s network to advance chemistry, manufacturing, and control (CMC) technologies and digitalization strategies.
- The collaboration is expected to apply cutting-edge research outcomes directly to strengthen CMC processes for drug product technologies.
- Experts from both industry and academia will work together to accelerate the adoption of automated manufacturing platforms and advanced CMC solutions.
Conclusion:
This partnership represents a strategic move for Lonza to enhance its capabilities in the pharmaceutical manufacturing landscape. By collaborating with CMAC, Lonza seeks to drive innovation and efficiency in drug development processes, ultimately benefiting its clients and reinforcing the industry’s shift toward more automated and effective manufacturing solutions.
